Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'

Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. PFE as his final trade on the latest edition of CNBC's “Halftime Report Final Trades.”

On Thursday, Pfizer announced it will advance the development of Danuglipron. The company selected the once-daily weight loss drug for continued advancement based on an ongoing pharmacokinetic study.

"Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates," said Mikael Dolsten, chief scientific officer & president, Pfizer Research and Development.

Bryn Talkington of Requisite Capital Management picked Invesco S&P 500 Equal Weight ETF RSP. “I think the market will continue to broaden out,” she added.

Bill Baruch of Blue Line Capital named VanEck Gold Miners ETF GDX as his final trade.

Don't forget to check out our premarket coverage here

Stephanie Link of Hightower picked L3Harris Technologies, Inc. LHX as her final trade.

L3Harris Technologies is scheduled to release its second quarter 2024 financial results on Thursday, July 25, after the closing bell. Analysts expect the company to report quarterly earnings at $3.16 per share, up from $2.97 per share in the year-ago period. The company is projected to post quarterly revenue of $5.29 billion, compared to $4.37 billion in the year-earlier quarter.

Price Action:

• L3Harris Technologies shares gained 1.4% to close at $230.34 on Thursday.
• Invesco S&P 500 Equal Weight ETF rose 1.2% during Thursday's session.
• VanEck Gold Miners ETF gained 2.8% on Thursday.
• Pfizer shares gained 1.1% to close at $28.66 during Thursday's session.

Check This Out:

• S&P 500 Falls Following June Inflation Data: Fear & Greed Index Moves To ‘Neutral’ Zone